Multiple endocrine neoplasia type 1 future or investigational therapies: Difference between revisions
No edit summary |
(Mahshid) |
||
(5 intermediate revisions by 2 users not shown) | |||
Line 2: | Line 2: | ||
{{Multiple endocrine neoplasia type 1}} | {{Multiple endocrine neoplasia type 1}} | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors ([[tropomyosin]] receptor kinase inhibitors), mTOR inhibitors, | Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors ([[tropomyosin]] receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping. | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
* Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.<ref name="pmidhttp://dx.doi.org/10.1210/jc.2012-1230">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1210/jc.2012-1230 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref> | * Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.<ref name="pmidhttp://dx.doi.org/10.1210/jc.2012-1230">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1210/jc.2012-1230 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref> | ||
Line 11: | Line 13: | ||
* Role of surgery for non functioning pancreatic [[neuroendocrine tumor]]s is also under investigation. | * Role of surgery for non functioning pancreatic [[neuroendocrine tumor]]s is also under investigation. | ||
* The interaction between menin and mixed lineage [[leukemia]] [[protein]] 1(MLL1) also known as a [[histone]] H3 [[lysine]] 4 methyltransferase has been targeted to find cure for multiple endocrine neoplasia type 1 | * The interaction between menin and mixed lineage [[leukemia]] [[protein]] 1(MLL1) also known as a [[histone]] H3 [[lysine]] 4 methyltransferase has been targeted to find cure for multiple endocrine neoplasia type 1 | ||
* | * Thienopyrimidine analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1. | ||
* Molecular | * Molecular phenotyping of [[tumor]]s have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage. | ||
== | |||
{{ | ==References== | ||
{{reflist|2}} | |||
[[Category:Oncology]] | |||
[[Category:Endocrinology]] | |||
[[Category: | {{WS}} | ||
{{WH}} | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Surgery]] |
Latest revision as of 02:45, 27 November 2017
Multiple endocrine neoplasia type 1 Microchapters |
Differentiating Multiple endocrine neoplasia type 1 from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multiple endocrine neoplasia type 1 future or investigational therapies On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 future or investigational therapies |
FDA on Multiple endocrine neoplasia type 1 future or investigational therapies |
CDC on Multiple endocrine neoplasia type 1 future or investigational therapies |
Multiple endocrine neoplasia type 1 future or investigational therapies in the news |
Blogs on Multiple endocrine neoplasia type 1 future or investigational therapies |
Directions to Hospitals Treating Multiple endocrine neoplasia type 1 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping.
Future or Investigational Therapies
- Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.[1]
- National and international collaborations are encouraged to recruit more patients with multiple endocrine neoplasia type 1 for clinical trials.
- Use of TRK inhibitors (tropomyosin receptor kinase inhibitors) for medullary thyroid cancer and pancreatic neuroendocrine tumors have been investigated under multicenter clinical trials.
- mTOR inhibitors for pancreatic neuroendocrine tumors are other subjects undergoing investigation.
- Role of surgery for non functioning pancreatic neuroendocrine tumors is also under investigation.
- The interaction between menin and mixed lineage leukemia protein 1(MLL1) also known as a histone H3 lysine 4 methyltransferase has been targeted to find cure for multiple endocrine neoplasia type 1
- Thienopyrimidine analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1.
- Molecular phenotyping of tumors have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage.
References
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID http://dx.doi.org/10.1210/jc.2012-1230 Check
|pmid=
value (help).